skip to content

Other

Abzena update on licensed product candidate

02 November 2016 07:53

Abzena notes that during the conference call to accompany Gilead Sciences Inc's announcement of third quarter earnings on 1 November, Gilead stated that no further development of simtuzumab will be pursued.

In addition, GS-5745 will not be progressed further for Crohns Disease.

This follows on from the announcement on 20 October of top line phase II clinical study results of Gilead's product, GS-4997 (selonsertib) in combination with the investigational monoclonal antibody, simtuzumab (SIM) or SIM alone, in patients with non-alcoholic steatohepatitis (NASH). Simtuzumab and GS-5745 are part of a range of products created using Abzena's Composite Human Antibody technology that its partners have been progressing in clinical development.

Story provided by StockMarketWire.com

Related Company: ABZA

Info Point:

To buy or sell shares call our Dealing Room on 0113 243 6941.

Too much jargon? Our glossary will help make sense of things.

Find out more about our Share Dealing Services.

Client Area Access

» Secure Login

» Not registered yet?

-

Branch Finder

Redmayne-Bentley have High Street branches throughout the UK. Find your nearest branch.